Stable aqueous formulations of adalimumab
View Patent ↗The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.
1. A stable aqueous pharmaceutical composition comprising:
(i) adalimumab;
(ii) buffer;
(iii) surfactant;
(iv) stabilizer; and
(v) sugar;
wherein the composition is free of mannitol and has a pH of about 5 to about 6.
2. The composition of claim 1 , wherein the buffer is selected from the group consisting of citrate, phosphate, succinate, histidine, tartrate maleate, and combinations thereof except the combination of citrate and phosphate.
3. The composition of claim 1 , wherein the buffer does not comprise citrate and the composition results in less pain upon administration to a subject in comparison to an adalimumab composition having a buffer comprising citrate.
4. The composition of claim 1 , wherein the surfactant is selected from the group consisting of polysorbate 80, polysorbate 40, and polysorbate 20.
5. The composition of claim 1 , wherein the stabilizer is selected from the group consisting of an amino acid, a salt, ethylenediaminetetraacetic acid (EDTA), and a metal ion.
6. The composition of claim 1 , wherein the stabilizer is selected from the group consisting of glycine, alanine, glutamate, arginine, methionine, EDTA, sodium chloride, sodium sulfate, metal ions, and combinations thereof.
7. The composition of claim 6 , wherein the stabilizer is combination of EDTA and one or more of glycine, alanine, glutamate, arginine, and methionine.
8. The composition of claim 1 , wherein the sugar comprises sucrose, glucose, lactose, maltose, and dextrose.
9. The composition of claim 1 , wherein the composition has a pH of about 5.5.
10. The composition of claim 1 , wherein the concentration of adalimumab is about 50 mg/ml.
11. The composition of claim 1 , wherein the composition has osmolality of about 180 to 420 mOsM; the composition is suitable for administration to a subject as a single dosage; the composition has a concentration of adalimumab in the range of 30 to about 50 mg/ml, and the dosage contains about 10 to 80 mg of adalimumab.
12. The composition of claim 11 , wherein the concentration of adalimumab is about 50 mg/ml and the dosage is about 40 mg.
13. A stable aqueous pharmaceutical composition comprising:
(i) adalimumab;
(ii) buffer;
(iii) surfactant;
(iv) amino acid;
(v) ethylenediaminetetraacetic acid (EDTA); and
(vi) sugar;
wherein the composition is free of citrate/phosphate buffer combinations, is free of mannitol, and has a pH of about 5 to about 6.
14. The composition of claim 13 , wherein the buffer is histidine.
15. The composition of claim 13 , wherein the surfactant is polysorbate 80.
16. The composition of claim 13 , wherein the amino acid is methionine.
17. The composition of claim 13 , wherein the sugar is sucrose.
18. The composition of claim 17 , wherein the composition has a pH of about 5.5.
19. The composition of claim 13 , wherein the concentration of adalimumab is about 50 mg/ml.
20. The composition of claim 13 , wherein the composition has osmolality of about 180 to 420 mOsM; the composition is suitable for administration to a subject as a single dosage; the composition has a concentration of adalimumab in the range of 30 to about 50 mg/ml, and the dosage contains about 10 to 80 mg of adalimumab.
21. The composition of claim 20 , wherein the concentration of adalimumab is about 50 mg/ml and the dosage is about 40 mg.
22. A stable aqueous pharmaceutical composition comprising:
(i) adalimumab;
(ii) histidine buffer;
(iii) polysorbate 80;
(iv) methionine;
(v) ethylenediaminetetraacetic acid (EDTA); and
(vi) sucrose;
wherein the composition is free of citrate/phosphate buffer combinations, is free of mannitol, and has a pH of about 5.5.
23. The composition of claim 22 , wherein the concentration of adalimumab is about 50 mg/ml.
24. The composition of claim 22 , wherein the composition has osmolality of about 180 to 420 mOsM; the composition is suitable for administration to a subject as a single dosage; the composition has a concentration of adalimumab in the range of 30 to about 50 mg/ml, and the dosage contains about 10 to 80 mg of adalimumab.
25. The composition of claim 24 , wherein the concentration of adalimumab is about 50 mg/ml and the dosage is about 40 mg.